We recently published a list of 11 Best Performing Large Cap Stocks So Far in 2025. In this article, we are going to take a ...

An unexpected disclosure rocked the health insurance world last week: CVS Health decided it was pulling out of the Affordable ...

The legislation would ensure Medicare beneficiaries have access to care and services provided by pharmacists within state ...

Gilead to Pay $202 Million to Settle DOJ Claims Over Speaker Program Kickbacks - Gilead Sciences, Inc. has agreed to pay $202 ...

On Friday, the company’s health services unit Evernorth unveiled new programs in a reliable growth area: helping payers ...

Biocon Biologics' Yesintek, a biosimilar to Stelara, has secured significant market access in the US, covering over 100 ...

Biocon Biologics Ltd. (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced the Company has secured multiple market access ...

Clinical studies showed that Yesintek is a biosimilar to Stelara and has similar pharmacokinetic, safety, efficacy and ...

Biocon Biologics secures market access agreements for Yesintek, a biosimilar to Stelara, for treating autoimmune diseases in ...

NRx stock has fallen over 2.8% this year. CVS Health Corp. (CVS) (+650% Weekly Message Volume) The health solutions giant ...